12:00 AM
 | 
Aug 07, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HumaRAD: Phase I/II

In a 10-patient Phase I/II trial, Intracel said that intratumoral injections of HumaRAD were well tolerated and achieved radiation doses sufficient to treat primary and...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >